Federal appeals court blocks mailing of mifepristone, limiting in-person clinic distribution

A federal appeals court restricts access to mifepristone, one of the most commonly used abortion medications in the United States, by blocking the mailing of the drug. Multiple outlets report that a three-judge panel of the New Orleans-based U.S. Court of Appeals for the Fifth Circuit issues the order, which prevents prescriptions from being distributed through the mail.

According to the reports, the ruling applies by requiring that mifepristone be dispensed only in person at clinics rather than via remote distribution. NPR, PBS NewsHour, MedPage Today, and STAT all describe the decision as a restriction on how the medication can be obtained following the court’s intervention.

MedPage Today and STAT also characterize the panel decision as unanimous, while the other outlets describe the ruling in terms of its practical effect on distribution methods. The court order therefore changes how patients can access mifepristone, limiting it to in-clinic dispensing rather than delivery by mail. The reports do not address broader policy outcomes beyond the specific distribution restriction included in the decision.